Company release, 22 March 2023 at 12 p.m. (EET)

Nightingale Health Plc ("Nightingale Health" or the "Company") published on 27 October 2022 its first consolidated financial statements prepared in accordance with IFRS for the financial year ended 30 June 2022. Before publishing the consolidated financial statements Nightingale Health provided comparative information on its consolidated statement of income, statement of financial position and key financials for the financial year ended 30 June 2021 and for the opening IFRS statement of financial position as at the transition date, 1 July 2020. The Company also announced that it will publish comparative IFRS information for the half-year periods ended on 31 December 2021 and 30 June 2022 before the publication of the H1/2022-2023 half-year report.

In this company release Nightingale Health publishes comparative IFRS information for the half-year periods ended on 31 December 2021 and 30 June 2022.

The financial information in this company release has not been audited.

Key financials for the half-year period 1 July 2021 – 31 December 2021

— Revenue was EUR 1,272 thousand

— EBITDA was EUR -4,128 thousand

— Operating loss was EUR -5,907 thousand

— Loss for the period was EUR -5,758 thousand

— Earnings per share (EPS) amounted to EUR -0.1 (Series A shares and EMP shares) and EUR -0.1 (Series B shares)

— Cash and cash equivalents at the end of the period totaled EUR 105,413 thousand

Key financials for the half-year period 1 January 2022 – 30 June 2022

— Revenue was EUR 1,041 thousand

— EBITDA was EUR -5,261 thousand

— Operating loss was EUR -7,727 thousand

— Loss for the period was EUR -10,332 thousand

— Earnings per share (EPS) amounted to EUR -0.17 (Series A shares and EMP shares) and EUR -0.17 (Series B shares)

— Cash and cash equivalents at the end of the period totaled EUR 95,279 thousand

Consolidated statement of income and comprehensive income 1 Jul 2021 – 31 Dec 2021*

EUR thousand

FAS
1 Jul 2021 –

31 Dec 2021

Total IFRS

adjustments

IFRS

1 Jul 2021 –

31 Dec 2021

Revenue

1,322

-50

1,272

Other income

20

1

21

Materials and services

-404

-

-404

Employee benefits

-1,139

-1,747

-2,887

Depreciation, amortization, and impairment losses

-1,526

-252

-1,778

Other expenses

-3,050

944

-2,107

Share of joint venture’s result

-2

-22

-24

Operating profit (loss)

-4,780

-1,126

-5,907

Finance income

171

-117

54

Finance costs

-453

-63

-515

Fair value change in investment in convertible loan

-

537

537

Net finance items

-281

357

76

Profit (loss) before tax

-5,062

-769

-5,831

Income tax expense

-1

73

72

Profit (loss) for the period

-5,063

-696

-5,758

Consolidated statement of comprehensive income

Profit (loss) for the period

-5,063

-696

-5,758

Other comprehensive income

Items that may be reclassified subsequently to profit or loss

Foreign operations - foreign currency translation differences, net of tax

-

-9

-9

Other comprehensive income for the period, net of tax

-

-9

-9

Total comprehensive income for the period

-5,063

-705

-5,768

Consolidated statement of income and comprehensive income 1 Jan 2022 – 30 Jun 2022*

EUR thousand

FAS

1 Jan 2022 –30 Jun 2022

FAS-

correction

Total IFRS adjustments

IFRS

1 Jan 2022 –

30 Jun 2022

Revenue

884

-

157

1,041

Other income

242

-

-

242

Materials and services

-633

-

-

-633

Employee benefits

-1,845

-

-1,767

-3,613

Depreciation, amortization, and impairment losses

-1,713

-

-753

-2,466

Other expenses

-3,262

-

963

-2,299

Share of joint venture’s result

23

-

-22

1

Operating profit (loss)

-6,305

-

-1,422

-7,727

Finance income

755

-

-124

631

Finance costs

-706

-

43

-663

Fair value change in investment in convertible loan

-4,103

588

910

-2,604

Net finance items

-4,053

588

829

-2,636

Profit (loss) before tax

-10,358

588

-593

-10,363

Income tax expense

45

-

-14

31

Profit (loss) for the period

-10,313

588

-607

-10,332

Consolidated statement of comprehensive income

Profit (loss) for the period

-10,313

588

-607

-10,332

Other comprehensive income

Items that may be reclassified subsequently to profit or loss

Foreign operations - foreign currency translation differences, net of tax

-

-

38

38

Other comprehensive income for the period, net of tax

-

-

38

38

Total comprehensive income for the period

-10,313

588

-569

-10,294

* A more detailed bridge calculation of the IFRS transition from the consolidated statement of income is presented in appendix A of this company release. The adjustments made are described in more detail in Note 2 Transition to IFRS of the consolidated financial statements of 1 July 2021–30 June 2022.

Consolidated statement of financial position 31 Dec 2021*

EUR thousand

FAS

31 Dec 2021

Total IFRS adjustments

IFRS

31 Dec 2021

Assets

Non-current assets

Goodwill

710

-247

463

Intangible assets

15,692

-1,746

13,946

Property, plant and equipment

1,460

1,580

3,041

Right-of-use assets

-

5,061

5,061

Equity-accounted investees

53

48

101

Investment in convertible loan

3,649

420

4,068

Other assets

491

-185

307

Total non-current assets

22,056

4,930

26,987

Current assets

Inventories

536

-

536

Trade and other receivables

1,197

-11

1,186

Cash and cash equivalents

105,413

-

105,413

Total current assets

107,147

-11

107,136

Total assets

129,203

4,920

134,123

Equity and liabilities

Equity

Share capital

80

-

80

Reserve for invested unrestricted equity

147,338

-5,010

142,327

Translation differences

3

-1

2

Retained loss

-27,097

4,854

-22,243

Total equity

120,324

-157

120,167

Liabilities

Non-current liabilities

Loans and borrowings

2,288

689

2,978

Lease liabilities

-

2,615

2,615

Total non-current liabilities

2,288

3,305

5,593

Current liabilities

Loans and borrowings

1,711

354

2,065

Lease liabilities

-

1,447

1,447

Advances received

1,701

-

1,701

Trade and other payables

3,179

-29

3,150

Total current liabilities

6,591

1,772

8,363

Total liabilities

8,879

5,077

13,956

Total equity and liabilities

129,203

4,920

134,123

* A more detailed bridge calculation of the IFRS transition from the consolidated statement of financial position is presented in appendix B of this company release. The adjustments made are described in more detail in Note 2 Transition to IFRS of the consolidated financial statements of 1 July 2021–30 June 2022.

For further information, please contact:

CEO Teemu Suna

ir@nightingalehealth.com

Certified Adviser:

Oaklins Merasco Ltd, tel. +358 9 6129 670

Appendices

Nightingale Health Plc Company release IFRS comparative information, which includes:

Appendix A Consolidated statement of income and consolidated statement of comprehensive income 1 Jul 2021 – 31 Dec 2021 and 1 Jan 2022 – 30 Jun 2022.

Appendix B Consolidated statement of financial position 31 Dec 2021

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.